Occlusion in the Flow of New Drugs for Cardiovascular Disease

There is a large misalignment between unmet need and both private and public investment activity in cardiovascular disease. In this paper we quantify the magnitude of the gap, analyze a range of potential root causes in two main categories (issues of feasibility or valuation), and propose steps toward solutions to close the gap. This article is protected by copyright. All rights reserved.